Carnegie Mellon University Professor Tsuhan Chen spent the early part of the week in Taipei, Taiwan, showcasing his ready-to-commercialize security technologies.
Dr. Chen has developed a software "toolbox" that, used with off-the-shelf security or surveillance cameras, can provide a do-it-yourself blueprint to track anything from cars in parking lots to home intruders.
The second technology, also developed in conjunction with his Taipei-based research partner, Shiaw-Shian Yu, is a motion sensor, which by using an algorithm can be trained to monitor and track the location of objects -- such as computers or suitcases -- and notify the owner when they are misplaced or stolen.
Both technologies were developed last year at the Industrial Technology Research Institute, a Taiwanese government-affiliated research center. Dr. Chen said the technology is ready to be sold on the market, but wouldn't say whether he'll launch his own company or license the technology to another firm. "At this point, I'm leaving all options open," he said.

Besides the obvious -- capital, which insiders say isn't so hard to come by in these parts -- reimbursement from Medicare for their medical devices or drug therapy products top the list.
"The reimbursement climate is very tricky," said Greenhouse executive-in-residence Lisa Parr. "These companies' viability is really based on whether or not they are able to get a third-party payer -- health insurers -- to reimburse them." The hardest part, she said, is trying to anticipate the type of clinical data a biotech company might need to support their case for reimbursement.
Greensburg-based medical device firm CardiacTelecom chief Lee Erhlichman concurred: "It's very hard to survive when costs are going up and reimbursements are going down." Other firms on hand to get face time with their federal representatives were Downtown-based BodyMedia, Marshall-based Renal Solutions, North Side-based Red Path Integrated Pathology and Braddock Hill-based MedSage Technologies.


A study commissioned by the Heinz Endowments has Beth Siegel, of Boston area-based consulting group Mt. Auburn Associates, talking to members of the local tech community to examine how local development groups that Heinz funds -- such as, but not limited to, the North Side-based Technology Collaborative and Oakland-based Idea Foundry -- are "performing and perceived." A Heinz spokesman said such assessments are routine and will not be made public.
And of course, there is the previously reported Battelle Technology Practice and Milken Institute study, charged with building a "roadmap" and "vision" for technology growth in the region. This project was commissioned by the Greater Oakland Keystone Innovation Zone, a designated area around Carnegie Mellon University, the University of Pittsburgh and the University of Pittsburgh Medical Center, that is eligible for tax breaks and grants to promote tech-based economic development.

